The latest results from SURPASS-4, the longest and largest completed SURPASS trial to date, showed consistent activity in maintaining A1C and weight control in the almost two years the study ran. SURPASS-4 is part of the Phase III trial evaluating tirzepatide as a potential treatment for type 2 diabetes.
Newly announced topline results from Eli Lilly’s SURPASS-4 trial program show the company’s investigational diabetes agent, tirzepatide, significantly reduced blood glucose levels and body weight better than insulin glargine in adult patients with type 2 diabetes.
Eli Lilly’s Phase III SURPASS-2 clinical trial shows that treatment with tirzepatide, a once-weekly dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist, is associated with superior reductions in body weight and blood sugar compared with injectable semaglutide in adults with type 2 diabetes.
The U.S. Food and Drug Administration approved Eli Lilly’s Lyumjev (insulin lispro-aabc injection, 100 units/mL and 200 units/mL), a new rapid-acting insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes.
Lilly’s diabetes drug Trulicity hit the mark in a late-stage trial showing higher doses of the medication significantly reduced A1C from baseline versus the product’s approved once-weekly usage.